AU4228397A - Cellular vaccines and immunotherapeutics and methods for their preparation - Google Patents
Cellular vaccines and immunotherapeutics and methods for their preparationInfo
- Publication number
- AU4228397A AU4228397A AU42283/97A AU4228397A AU4228397A AU 4228397 A AU4228397 A AU 4228397A AU 42283/97 A AU42283/97 A AU 42283/97A AU 4228397 A AU4228397 A AU 4228397A AU 4228397 A AU4228397 A AU 4228397A
- Authority
- AU
- Australia
- Prior art keywords
- cells
- cell
- target diseased
- molecules
- diseased cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 74
- 229940030156 cell vaccine Drugs 0.000 title description 13
- 238000002360 preparation method Methods 0.000 title description 5
- 230000001024 immunotherapeutic effect Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 363
- 108090000695 Cytokines Proteins 0.000 claims description 95
- 102000004127 Cytokines Human genes 0.000 claims description 92
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 79
- 230000000139 costimulatory effect Effects 0.000 claims description 79
- 239000000427 antigen Substances 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 68
- 102000036639 antigens Human genes 0.000 claims description 68
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 67
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 67
- 210000004881 tumor cell Anatomy 0.000 claims description 64
- 230000006044 T cell activation Effects 0.000 claims description 56
- 230000027455 binding Effects 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 51
- 230000002163 immunogen Effects 0.000 claims description 45
- 241000124008 Mammalia Species 0.000 claims description 39
- 101710170453 Glycoprotein 55 Proteins 0.000 claims description 33
- 239000012636 effector Substances 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 18
- 210000000265 leukocyte Anatomy 0.000 claims description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 15
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 13
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 12
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 11
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 11
- 108010074328 Interferon-gamma Proteins 0.000 claims description 11
- 102100037850 Interferon gamma Human genes 0.000 claims description 10
- 102000043129 MHC class I family Human genes 0.000 claims description 9
- 108091054437 MHC class I family Proteins 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 7
- 102100032912 CD44 antigen Human genes 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010048623 Collagen Receptors Proteins 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 3
- 102000009109 Fc receptors Human genes 0.000 claims description 3
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims description 3
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 108010001831 LDL receptors Proteins 0.000 claims 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 62
- 238000000338 in vitro Methods 0.000 description 39
- 239000000126 substance Substances 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 32
- 238000001727 in vivo Methods 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 21
- -1 CD15S Proteins 0.000 description 17
- 230000036039 immunity Effects 0.000 description 16
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 15
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 13
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 13
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 13
- 229940045513 CTLA4 antagonist Drugs 0.000 description 12
- 102100025390 Integrin beta-2 Human genes 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000003393 splenic effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 10
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 10
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000005229 liver cell Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 230000005809 anti-tumor immunity Effects 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 101150089247 B7 gene Proteins 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108010045634 B7 Antigens Proteins 0.000 description 3
- 102000005738 B7 Antigens Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100036008 CD48 antigen Human genes 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 3
- 102100025323 Integrin alpha-1 Human genes 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100022337 Integrin alpha-V Human genes 0.000 description 2
- 108010041341 Integrin alpha1 Proteins 0.000 description 2
- 108010055795 Integrin alpha1beta1 Proteins 0.000 description 2
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101710165202 T-cell surface antigen CD2 Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000010910 CD28 Antigens Human genes 0.000 description 1
- 108010062433 CD28 Antigens Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102000024905 CD99 Human genes 0.000 description 1
- 108060001253 CD99 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102100031699 Choline transporter-like protein 1 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025877 Complement component C1q receptor Human genes 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000940912 Homo sapiens Choline transporter-like protein 1 Proteins 0.000 description 1
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000604993 Homo sapiens Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 101001070786 Homo sapiens Platelet glycoprotein Ib beta chain Proteins 0.000 description 1
- 101001033026 Homo sapiens Platelet glycoprotein V Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 102100033000 Integrin beta-4 Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 102100034168 Platelet glycoprotein Ib beta chain Human genes 0.000 description 1
- 102100038411 Platelet glycoprotein V Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241001291896 Streptococcus constellatus Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940030547 autologous tumor cell vaccine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229940037648 staphylococcus simulans Drugs 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
CELLULAR VACCINES AND IMMUNOTHERAPEUTICS AND METHODS FOR THEIR PREPARATION
RELATED APPLICATION The present application claims the priority benefits of U.S. provisional application 60/019,639, filed June 12, 1996.
FIELD OF THE INVENTION
The present invention provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic cells in order to provide the immune system with an immunogenic signal capable of stimulating T cell activation leading to an effective immune response. The method of the invention generates cellular vaccines which are useful for the prevention and treatment of diseases which develop and/or persist by escaping the immune response triggered by T cell activation. Such diseases include, for example, all cancers, natural and induced immune-deficiency states, and diseases caused by infections with a variety of pathogens.
BACKGROUND OF THE INVENTION
U.S. patent 5,484,596 by Hanna et al. describes using tumor tissue as a vaccine. U.S. Patent 4,844,893 by Honsik et al . describes arming IL-2-activated leukocytes with Mabs directed to antigens preferentially expressed on tumor cells for killing the target cells. Both patents are incorporated by reference herein.
Anti-tumor immune responses are mediated primarily by T
lymphocytes. Down regulation of both the major histocompatibility complex (MHC) and the molecules that costimulate the immune response is associated with defective T cells activation signaling by tumor cells (Luboldt et al. , Cancer Res. 56:826-830, 1996; L. Chen et al. , 1992, Cell 1: 1093; P.S. Linsley, J. A. Ledbetter, 1993, Ann. Rev. Immunol H: 191; G.J. Freeman et al., 1993, Science 262: 909; CH. June et al. , 1994, Immune. Today 15.: 321; J. T. Gerge et al. , 1993, Cancer Res. 53 : 2374; Ostrand-Rosenberg, 1993, S. Curr. Opin. Immune. £.: 772; B. E. Elliot et al. , 1989, Adv. Cancer Res. 53: 181).
T cell receptor (TCR) recognition of MHC-bound antigen is not a sufficient signal for T cell activation. Costimualtory molecules, such as B7-1 and B7-2, are cell surface proteins of antigen presenting cells (APCs) , and other cells targeted by the immune response, that provide critical signals for T cell activation (for review, see L. Chen et al. , 1995, Immunol. Rev. 145: 123; T. Tykocinski et al., 1996, Am. J. Path. 148: 1) . B7 signaling via the T cell surface molecule CD28 appears to be the major costimulatory pathway for T cell activation. However, recent studies show that costimulation is a more complex event which involves both cytokines and adhesion molecules (G. Yang et al., 1995, J. Immune. 154: 2794; M. Kubin et al. , 1994, J. Exp. Med. ULQ_: 211; Y. Li et al. , 1996, J. Exp. Med. 1JL3_: 639) .
Many approaches have been used to enhance the immunogenicity of tumor cells (see, for example, the references cited in this section) . The major approaches presently under investigation involve gene transfer. In this regard, most of the methods
employed to date have required ex vivo or in vivo transfection with genes such as MHC or B7, or modification of tumor cells with antigen presenting cells (APCs) (Y. J. Guo et al. , 1994, Science 2£3_: 518; M. Tykocinski, 1996, A. J. Path. 14J.: 1; J. Young and K. Inaba, 1996, J. Exp. Med. 18_3_: 7; L. Zitvogel et al. , 1996, J. Exp. Med. 1£3_: 87; C. M. Celluzzi et al. , 1996, J. Exp. Med. 1£3_: 283) . These approaches are time consuming and problematic because of the poor transfectability of primary tumor cells and because of the requirement for large numbers of APCs. In vitro treatment of tumor cells with cytokines increases the expression of MHC and adhesion molecules (R. Mattsson et al . , 1992, Biol-Reprod 46 : 1176; R. J. Ulevitch et al . , 1991, Am. J. Pathol. 139: 287; F. Willems et al. , 1994, Eur. J. Immune. 24.: 1007; I. Saito et al. , 1993, J. Clin. Lab. Anal. 1 : 180; R. A. Panettieri et al. , 1994, J. Immune. 154 : 1358; M. Ikeda et al. ,
1994, J. Invest. Dermatol. 103 : 791) . Transfection of tumor cells with MHC, B7-1 and B7-2 genes converts low immunogenic tumor cell lines to immunogenic cell lines (S. E. Townsend and J. P. Allison, Science 25_9_: 368; J. P. Allison et al. , 1995, Curr. Opin. Immune. J_ : 682; G. Yang et al. , 1995, J. Immune. 154 : 2794; M. Kubin et al. , 1994, J. Exp. Med. 180 : 211) . Non-immunogenic tumor cells are not responsive to transfection with the B7 gene alone but can become responsive by co-expression of CD48 molecules at the cell surface (Y. Li et al., 1996, J. Exp. Med. 1&3_: 639) .
The costimulatory molecule B7 can under some circumstances deliver a negative signal through its binding to CTLA-4, a second
receptor for B7 on T cells. Cross-linking CTLA-4 molecules in vitro has been shown to inhibit T cell proliferation. Furthermore, mice deficient in CTLA-4 develop severe T cell proliferative disorders (K. Kawai et al., 1993, Science 261: 609; J. P. Allison, M. K. Krummel, 1995, Science 270: 932; J.M. Green et al., 1994, Immunity 1: 501) . A recent report showed that the introduction of anti-CTLA-4 monoclonal antibody (MAb) , which blocks CTLA-4 mediated signaling, resulted in enhanced T cell- dependent rejection of tumors in certain mouse models (D.R. Leach et al., 1996, Science 271 : 1734) . These data provide evidence that CTLA-4 may be counter-regulatory to the CD28 costimulatory signal. Thus, transfected tumor cells expressing B7 molecules may fail to elicit effective immunity due to CTLA-4 mediated negative signaling. In addition to T cell activation using B7 gene transfection, bispecific monoclonal antibodies (Bi-MAbs) in combination with pre-stimulated lymphocytes have been used to induce T cell activation under certain circumstances. For example, one study reports that costimulatory signals can be delivered by a combination of Bi-MAbs to CD28:CD30 (CD30 is a Hodgkin's tumor- associated antigen) and CD3:CD30 in combination with peripheral blood lymphocytes (PBLs) pre-stimulated with the CD3:CD30 Bi-MAb in the presence of CD30+ Hodgkin's tumor-derived cells; however, the combination of CD28:CD30 and CD3:CD30 Bi-MAbs alone did not induce significant in vitro cytotoxicity of resting human PBLs against a Hodgkin's tumor-derived cell line, and stimulation with the CD28:CD30 Bi-MAb alone was not effective (C. Renner et al. ,
1994, Science 264: 833) . Similarly, regression of Hodgkin's derived tumor xenografts was observed only when both the CD28:CD30 and CD3:CD30 Bi-MAbs were used in combination with PBLs prestimulated in vitro with CD30+ cells and CD3:CD30 Bi-MAb; no significant effect was observed in xenografts treated with either of the Bi-MAbs alone, or a combination of the two Bi-MAbs without prestimulated human PBLs (Renner et al. , supra) .
SUMMARY OF THE INVENTION The present invention features immunogenic tumor cells and other immunogenic autologous cells, convenient methods of making such immunogenic cells, methods of using such immunogenic cells to activate or enhance immune response against diseased cells with minimum effect on normal or healthy cells, and methods of avoiding the negative T cell signaling pathway.
The present invention provides a method for enhancing the immunogenicity of weakly-immunogenic or non-immunogenic cells, resulting in a cellular vaccine that can stimulate T cell activation, which in turn leads to an effective immune response against diseased cells. The cellular vaccines of the present invention can be used as vaccines to prevent diseases and as immunotherapeutics to treat diseases.
In summary, the method of the invention involves the steps of (1) treating weakly- or non-immunogenic autologous cells (target cells) in order to amplify primary and costimulatory T cell activation signals in the cells, and (2) attaching to the treated cells a substance capable of binding to one or more
antigens on the treated cells and to one or more T cell activation costimulatory molecules on the surface of T cells (such as CD28) , thereby providing the treated cells with the capacity to physically link to T cells and to activate the costimulatory signal. Such substances include, but are not limited to, bispecific monoclonal antibodies (Bi-MAbs) targeted to antigen on the treated cells and to CD28 and/or other costimulatory molecules on T cells. The first step may be skipped when the autologous cell is attached with (1) a bridge molecule with two or more binding sites for T cell activation costimulatory molecules on the surface of T cells, or (2) two or more bridge molecules each with one or more binding sites for T cell activation costimulatory molecules on the surface of T cells. Once the primary and/or costimulatory T cell activation signals in the target diseased cells have been amplified by cytokines or other means and the bridge molecules have been attached to the target diseased cells, the cytokines and the bridge molecules not attached to the target diseased cells may be removed from the immunogenic composition before the target diseased cells are administered to a patient. This additional step minimizes adverse effects associated with administering cytokines to a patient. It also minimizes the risk associated with allowing bridge molecules not attached to a target diseased cell into a patient, an event which may cause unwanted immune response against normal or healthy cells.
The first step of the method up-regulates antigen processing
capacity within the treated cells and amplifies the expression of cell surface molecules involved in T cell activation. The second step provides the treated cells with a means to physically bridge to T cells via CD28 and/or other costimulatory molecules, thereby providing optimal conditions for stimulating T cell activation. Thus, in a first aspect, this invention features an immunogenic composition for administration to a patient mammal (including a human) having target diseased cells. The immunogenic composition contains an autologous target diseased cell which differs from the diseased cells in the patient in that it processes and presents antigens characteristic of the diseased cells more effectively. For example, the autologous target diseased cell expresses one or more primary (e.g., MHC) and/or costimulatory (e.g., B7-1 and B7-2) T cell activation molecules at a higher level (e.g., 50% higher, preferably 2 folds higher, more preferably 10 folds higher) . As described below, there are different ways of enhancing the expression level of the primary and/or costimulatory T cell activation molecules.
In addition, the autologous target diseased cell has attached thereto one or more bridge molecules. Each bridge molecule has one or more binding sites for one or more costimulatory molecules on the surface of effector cells, which include, but are not limited to, T cells, NK cells, macrophages, LAK cells, B cells, and other white blood cells. Preferably, though not required, the bridge molecules have one or more binding sites for one or more antigens on the surface of the target diseased cell and are attached to the target diseased
cells at the cell surface antigens. In another preferred embodiment, substantially all (e.g., >80%, preferably >90%, more preferably >95%) the bridge molecules in the immunogenic composition are attached to the autologous target diseased cells so that the composition is substantially free of bridge molecules not attached to a target diseased cell. In a further preferred embodiment, the immunogenic composition contains a pharmaceutically effective amount of the target diseased cells with bridge molecules attached thereto. By "immunogenic" is meant the ability to activate the response of the whole or part of the immune system of a mammal, especially the response of T cells.
By "autologous" is meant that the target diseased cell is from the patient mammal, or from another patient having a common major histocompatibility phenotype. An autologous target cell may be obtained from the patient mammal or another source sharing the same MHC with methods known to those skilled in the art.
By "target diseased cell" is meant a cell causing, propagating, aggravating or contributing to a disease in a patient mammal. Target diseased cells include, but are not limited to, tumor cells (including unmodified tumor cells, tumor cells modified with different approaches, and primary culture) . The sources of tumor cells include, but are not limited to, liver cancer, hepatocellular carcinoma, lung cancer, gastric cancer, colorectal carcinoma, renal carcinoma, head and neck cancers, sarcoma, lymphoma, leukemia, brain tumors, osterosarcoma, blade carcinoma, myloma, melanoma, breast cancer, prostate cancer,
ovarian cancer, and pancreas carcinoma.
Target diseased cells may also be cells infected with prions (which cause Mad Cow diseases among others) , viruses, bacteria, fungi, protozoa or other parasites (e.g. worms) . Viruses include those described or referred to in Fields Virology. Second Edition. 1990, Raven Press, New York, incorporated by reference herein. Examples include, but are not limited to, herpes virus, rhinoviruses, hepatitis virus (type A, B, C and D) , HIV, EBV, HPV, and HLV. Bacteria include those described or referred to in Bergey's Manual of Determinative Bacteriology. Ninth Edition. 1994, Williams and Wilkins, incorporated by reference herein. Examples include, but are not limited to, gram positive and negative bacteria, streptococci , pseudomonas and enterococci , MycoJbacterium tuberculosis, Aeromonas hydrophilia, Aeromonas caviae, Aeromonas βobria, Streptococcus uberis, Enterococcus faecium, Enterococcus faecalis, Bacillus sphaericus, Pseudomonas fluorescens, Pseudomonas putida, Serratia liquefaciens, Lactococcus lactis, Xanthomonas mal tophilia, Staphylococcus simulans , Staphylococcus hominis, Streptococcus constellatus,
Streptococcus anginosus, Escherichia coli , Staphylococcus aureus, Mycobacterium fortui tum, and Klebεiella pneumonia .
Primary T cell activation molecules include MHC class I, MHC class II and other molecules associated with antigen processing and/or presentation. Costimulatory T cell activation molecules include ICAM-1, ICAM-2, ICAM-3, LFA-1, LFA-2, VLA-1, VCAM-1, 4-1- BB, B7-1, B7-2, and other cell adhesion proteins and other cell
surface proteins which can activate T cell costimulatory pathways through T cell surface proteins.
By "bridge molecule" is meant a molecule or substance which can bring two or more cells together by attaching to the cells with its binding sites. Preferably, a bridge molecule can bring an autologous target diseased cell together with an effector cell and deliver a signal to the effector cell to activate or enhance the effector cell's immune response against the target. A bridge molecule has one or more binding sites for stimulatory and/or costimulatory molecules on the effector cells. These binding sites can be designed to activate a positive regulator of T cell activation (e.g., CD28, 4-1BB) but avoid stimulating a negative regulator of T cell activation (e.g., CTLA-4) . The binding sites can also be designed to blockade a negative regulator of T cell activation (see Leach et al . , Science 271:1734-1736, 1996) . A bridge molecule may also have one or more binding sites for antigens on the surface of the target diseased cell. Bridge molecules include, but are not limited to, bispecific monoclonal antibodies, fusion proteins, organic polymers, and hybrids of chemical and biochemical materials. The antibodies described or disclosed in U.S. patents 5,601,819, 5,637,481, 5,635,602, 5,635,600, 5,591,828, 5,292,668 and 5,582,996 are incorporated by reference herein.
The antigen on the target cell serving as an anchor for the bridge molecule need not be unique to the target cell when the bridge molecule is attached to the target cell in vi tro. Any molecule on the target cell surface can be used to anchor the
bridge molecule, including, but not limited to, proteins, glycoproteins, lipids, glycolipids, phospholipids, lipid aggregates, steroids, and carbohydrate groups such as disaccharides, oligosaccharides and polysaccharides (see "Molecular Biology of The Cell," pp47-58, pp276-337, Second Edition, published by Garland Publishing, Inc. NY & London) . Examples include transferrin receptor, Low Density Lipoprotein (LDL) receptor, gp55, gp95, gpll5, gp210, CD44, ICAM-1, ICAM-2, collagen and fibronectin receptor, transferrin receptors, Fc receptor, and cytokine receptors.
Costimulatory molecules on the surface of effector cells may be antigens, fatty acids, lipids, steroids and sugars that can stimulate or costimulate these effector cells' functions to destroy the target cells. Costimulatory molecules include, but are not limited to, CDla, CDlb, CDlc, CD2, CD2R, CD3, CD4, CD5,
CD6, CD7, CD8, CD9, CD10, CDlla, CDllb, CDllc, CDwl2, CD13, CD14, CD15, CD15S, CD16a, CD16b, CDwl7, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD44R, CD45, CD45RA, CD45RB, CD45R0,
CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD51/61 complex, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CDw60, CD61, CD62E, CD62L, CD62P, CD63, CD64, CDw65, CD66a, CD66b, CD66c, CD66d, CD66e, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CDw75, CDw76, CD77, CDw78, CD79a, CD80, CD81, CD82, CD83, CDw84, CD85, CD86, CD87, CD88, CD89, CDw90, CD91, CDw92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CDwlOl,
12
CD102, CD103, CD104, CD105, CD106, CD107a, CD107b, CDwlOδ, CDW109, CD110-CD114, CD115, CDwll6, CD117, CD118*, CD119, CD120a, CD120b, CDwl21a, CDwl21b, CD122, CD123*, CDwl24, CD125*, CD126, CDW127, CDW128, CD129, CDwl30, LFA-1, LFA-2, LFA-3, VLA-1,VCAM-1, VCAM-2, 4-IBB, cytokine and chemokin receptors. In a preferred embodiment, the bridge molecule has a binding site for CD28 or 4- 1BB on the surface of T cells.
By "pharmaceutically effective" is meant the ability to cure, reduce or prevent one or more clinical symptoms caused by or associated with the diseased cells in the patient mammal, including, but not limited to, uncontrolled cell proliferation, bacteria infection, and virus infection.
The immunogenic composition may be isolated, enriched or purified for administration to a patient. By "isolated" in reference to the immunogenic composition is meant that the autologous target diseased cell is isolated from a natural source. Use of the term "isolated" indicates that one or more naturally occurring materials have been removed from the normal environment. Thus, the target diseased cell may be placed in a different cellular environment or in a solution free of other cells. The term does not imply that the target diseased cell is the only cell present, but does indicate that it is the predominate cell present (at least 20 - 50% more than any other cells) and is essentially free (about 90 % pure at least) of other tissues naturally associated with it in the body of the patient. In a preferred embodiment, the composition is substantially free of effector cells such as T cells. In another
preferred embodiment, the composition is substantially free of bridge molecules not attached to a target diseased cell. In a third preferred embodiment, the composition is substantially free of cytokines outside of the target diseased cell. By "enriched" in reference to the immunogenic composition is meant that the autologous target diseased cell constitutes a significantly higher fraction (2 - 5 fold) of the total cells in the composition than in the diseased tissue in the patient's body. This could be caused by a person by preferential reduction in the amount of other cells present, or by a preferential increase in the amount of the specific target diseased cells, or by a combination of the two. However, it should be noted that enriched does not imply that there are no other cells present, just that the relative amount of the cell of interest has been significantly increased in a useful manner. The term
"significantly" here is used to indicate that the level of increase is useful to the person making such an increase, and generally means an increase relative to other cells of about at least 2 fold, more preferably at least 5 to 10 fold or even more. By "purified" in reference to the immunogenic composition does not require absolute purity (such as a homogeneous preparation) ; instead, it represents an indication that the target diseased cell is relatively purer than in the natural environment. The target diseased cells could be obtained directly from the patient or from cell culture, with or without modifications. Purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five
orders of magnitude is expressly contemplated. In a preferred embodiment, the composition is substantially free of effector cells such as T cells.
The immunogenic composition may contain a pharmaceutically suitable carrier or excipient. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences. 18th ed., Mack Publishing Co., Easton, PA (1990) . The immunogenic composition may be administered to a patient systemically, e.g., by intravenous infusion or subcutaneous injection. A composition of the invention may be administered as a unit dose to a patient mammal, each unit containing a predetermined quantity (e.g., about 1x10s to about lxlO10, preferably about lxlO6 to about lxlO9, and more preferably about lxlO7 to about lxlO8) of armed and/or activated autologous target diseased cells calculated to produce the desired therapeutic effect in association with the physiologically tolerable aqueous medium as diluent.
The expression of primary and costimulatory T cell activation molecules may be enhanced by various means, for example, in vi tro, ex vivo or in vivo treatment of target cells with cytokines or other factors capable of inducing the desired amplification; and in vi tro and in vivo transfer to the target cells of MHC genes, adhesion molecule genes, cytokine genes, and/or their respective transcription activators or enhancers. Cytokines include those described or referred to in The Cytokine Handbook. Thomson, A., (ed.) , 1994, Academic Press, San Diego, incorporated by reference herein. Examples include, but are not
limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, inteferons (e.g., IFN α, β, and γ) , tumor necrosis factors (e.g., TNF α, and β) and other chemokines and lymphokines. In a preferred embodiment, IFN γ and TNF α are used either alone or in combination to enhance the expression of primary and costimulatory T cell activation molecules in autologous target diseased cells.
When a target diseased cell coated with bridge molecules is administered into a patient, it will bind to costimulatory molecules on the surface of the effector cells. The more densely the target diseased cell is coated with bridge molecules, the' more effector cells it will be able to bind. In addition, the more binding sites a bridge molecule has for the costimulatory molecules, the more effector cells it will be able to bind.
In that regard, Applicant has found that a cellular vaccine may be prepared without the need of cytokine treatment (to increase the levels of primary and costimulatory T cell activation molecules) when a plurality of bridge molecules are attached to a target cell with binding sites for two or more different costimulatory molecules on the surface of T cells. Individual bridge molecules may be attached to different anchor molecules on the surface of the target diseased cell. An individual bridge molecule may also have two or more binding sites for two or more different costimulatory molecules on the surface of T cells.
Thus, in a second aspect, this invention features an
immunogenic composition containing an autologous target diseased cell having attached thereto (a) a bridge molecule which has two or more binding sites for two or more different effector cells, (b) a bridge molecule which has two or more binding sites for two or more different costimulatory molecules on the surface of effector cells, (c) two or more bridge molecules each containing a binding site for a different effector cell, (d) two or more bridge molecules each containing a binding site for a different costimulatory molecule on the surface of effector cells, (d) two or more bridge molecules each attached to a different antigen on the target cells, or (e) a combination of two or more of the above.
A pharmaceutically effective amount of an immunogenic composition of this invention may be complemented by a pharmaceutically acceptable carrier before administration to a patient mammal.
Alternatively, a patient may be administered with a pharmaceutical composition containing (1) a pharmaceutically effective amount of a cytokine capable of increasing the level of one or more primary and costimulatory T cell activation molecules in tumor cells, (2) a pharmaceutically effective amount of a bridge molecule containing a binding site for an antigen on the surface of the tumor cells and a binding site for a costimulatory molecules on the surface of T cells, and (3) a pharmaceutically acceptable carrier.
In treating a patient, the autologous target cell may be treated with cytokines or other means of increasing primary and
costimulatory T cell activation molecules in vi tro before the target cell is administered to the patient. Alternatively, the cytokines may be administered to the patient to increase primary and costimulatory T cell activation molecules in vivo . In a third aspect, this invention features a method of generating cytotoxic leukocytes against diseased cells in a patient mammal by contacting a population of effector cells (e.g., white blood cells) in vi tro with immunogenic compositions described above for a time period sufficient to react with the immunogenic compositions and collecting the treated effector cell population. The cytotoxic leukocytes so generated can then be administered to a patient to treat or prevent diseases.
The method of the invention is useful for the prevention and treatment of diseases which develop and/or persist by escaping immune responses triggered by T cell activation. Such diseases include, for example, all cancers, natural and induced immune deficiency states, and diseases caused by infections with a variety of pathogens. The method of the invention is illustrated herein by demonstrating its application to three different types of human cancers. Cancer cells are by nature generally weakly immunogenic, fail to trigger an effective T cell response, and survive and grow as a result. As demonstrated herein, cancers can be prevented, and established cancers may be cured, by stimulating an effective T cell response using autologous tumor cell vaccines of the invention.
Other features and advantages of the invention will be apparent from the following detailed description of the
invention, and from the claims.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. Expression of MHC class I, ICAM-1, ICAM-2 and VCAM-1 antigens on cytokine treated hepa 1-6 cells. The results are representative data from four comparable experiments.
FIG. 2. Stimulation and proliferation of syngeneic splenic T cells in vitro induced by cytokine treated hepa 1-6 cells and anti-CD28 MAb. FIG. 3. Cytotoxicity of CTLs generated by in vitro priming of naive splenic T cells with cytokine treated hepa 1-6 cells in- combination with anti-CD28 Bi-MAbs or control MAb.
FIG. 4. Induction of protective immunity with cytokine treated hepa 1-6 cells armed with anti-CD28 Bi-MAb. FIG. 5. Tumor rejection following treatment with cytokine treated hepa 1-6 cells armed with CD28:gp55 Bi-MAb.
FIG. 6. Cure of established hepatomas in vivo. FIG. 7. Therapeutic effectiveness of γ-irradiated cytokine treated hepa 1-6 cells armed with CD28:gp55 Bi-MAb.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides methods for immunizing individuals against disease and for treating individuals with established diseases using cellular vaccines created with a two- step process described herein. The methods of the invention may be applicable to any disorder involving a low- or non-immunogenic response pathology, wherein effective treatment or prophylaxis
requires an immune boost through activation of T cells. Such disorders include, but are not limited to, all forms of cancer, immune deficiency disorders (both natural and induced) , and infectious diseases caused by viral or other pathogenic agents. The methods of the invention comprise modifying weakly- or non-immunogenic autologous cells of the disorder (target cells) by (1) treating the target cells in order to amplify primary and costimulatory T cell activation signals therein, and (2) attaching to the target cells a substance capable of binding to one or more antigens on the target cells and to one or more T cell activation costimulatory molecules on the surface of T cells (i.e., CD28) , thereby providing the target cells with the capacity to physically link to T cells and activate the costimulatory signal. Such substances include, but are not limited to, bispecific monoclonal antibodies (Bi-MAbs) targeted to antigen on the treated cells and to CD28 and/or other costimulatory molecules on T cells.
The first step of the method amplifies the expression of cell surface molecules involved in T cell activation, such as MHC and adhesion molecules, and up-regulates antigen processing capacity within the target cells by enhancing enzyme activity involved in intracellular antigen processing. For the first step of the method, any means which can amplify primary and costimulatory T cell activation signals in the target cells (i.e., the expression of MHC and adhesion molecules), may be used. Such amplified expression may be achieved by, for example, in vitro and in vivo treatment of target cells with cytokines or
other factors capable of inducing the desired amplification; and in vitro and in vivo transfer of MHC genes, adhesion molecule genes, cytokine genes, and/or MHC, adhesion molecule, and cytokine gene transcription activators or enhancers to the target cells.
In one embodiment of the method, amplification of primary and costimulatory T cell activation signals in the target cells is achieved using cytokine treatment. Target cells may be treated with cytokines ex vivo or in vitro as described in the examples herein. Alternatively, cytokines may be administered to the target cells in vivo by, for example, intralesional injection, intralymph injection, subcutaneous injection, etc., in suitable pharmaceutical carriers or controlled release preparations. Any cytokine or combination of cytokines which results in the amplified expression of MHC and adhesion molecules may be used to treat cells in the first step of the method. In preferred embodiments, described more fully by way of the examples herein, a combination of interferon (IFN-γ) and tumor necrosis factor-α (TNF-α) is used in the first step. Preferably, cells may be treated with concentrations of between about 10 - 100 U IFN-γ in combination with concentrations of between about 10-100 U TNF-α, more preferably with 100 U IFN-γ, and 50 U TNF-α, as described in Section 6.1., infra. However, the conditions and specific cytokines most optimal for the amplification of activation signals on the particular cells to be treated may vary and may be determined essentially as described in Section 6.1., infra.
The second step of the method of the invention provides the treated cells with the capacity to physically bridge to T cell surfaces via CD28 and/or other T cell costimulatory molecules, thereby providing optimal conditions for stimulating T cell activation. For the second step, any substance capable of binding to one or more antigens on the treated cells and to one or more T cell activation costimulatory molecules on the surface of T cells may be used. Such bispecific or multispecific bridging substances may comprise, for example, Bi-MAbs, proteins and other macromolecules, and polymer materials, which contain a functionality capable of binding to the targeted T cell costimulatory molecule and activating, or inducing the activation of, the costimulatory signal. In one embodiment, described by way of the examples in Section 6, infra, Bi-MAbs are used as the bridging substance.
One functionality of the bispecific or multispecific bridging substance may be directed to a target cell-specific antigen or any antigen expressed on the target cells. Optimally, where the target cells are to be armed with bridging substance in vivo, the target cell antigen to which the bridging substance is directed should be unique.
However, the target cell antigen need not be unique to the treated cells, since the attachment of the bridging substance may be practiced in vi tro . Accordingly, bridging substances attached to the target cells in vi tro will not cross-react with the same antigen on cells in the individual to be immunized with the modified cells.
After such bridging substances are incubated with cells treated according to the first step of the method, free bridging substance may be washed away and bound bridging substance may be cross-linked to the cell surface with polyethylene glycol (PEG) or another cross-linking agent.
Another functionality of the bispecific or multispecific bridging substance is specifically directed to a T cell activation costimulator such as CD28. Thus, when the modified cells are used to immunize an individual, the CD28 (or other costimulatory molecule) binding sites of the attached bridging substance are free, and will bind to CD28 (or other costimulatory molecule) on T cell surfaces, ensuring that the modified cells will become physically linked to T cells. This bridging substance-mediated physical link also brings other molecules on the surfaces of the modified cells, some of which have been amplified by the cytokine treatment step, into contact with other molecules on the surfaces of T cells, providing further costimulation which thereby further facilitates T cell activation. The second step of the method may be practiced in vitro or in vivo, depending upon whether target cells were treated according to the first step of the method in vivo or in vitro, the circumstances of the disease or lesion to be treated, and the clinical objectives of the treatment. Where the first step of the method is conducted in vivo, the treated cells may be armed with the bridging substance in vivo as well. In this case, the clinician may use a variety of known methods for administering
the bridging substance to a patient . The best route of administering the bridging substance to patients who have had disease- or lesion- specific cells (target cells) treated in vivo according to the first step of the method will depend on clinical and/or other aspects of the disease or lesion to be treated as well as on the site of the treated cells. For example, where target cells located in lymph node have been treated in vivo, direct administration of the bridging substance to the lymph node is preferred. Similarly, for example, where tumor cells have been treated in vivo by intratumor injection of cytokines or gene transfer vectors, the bridging substance preferably should be administered directly into the tumor or to the local environment of the tumor.
Where the first step of the method is conducted in vitro, the treated cells may be armed with the bridging substance in vivo or in vitro. Where the bridging substance is administered in vivo, the same route used to administer the treated cells or a similar route should be used, taking into account the same factors discussed above regarding in vivo arming of in vivo treated target cells.
When in vitro treated cells are armed in vitro, the treated and armed cells (cellular vaccine) may be used in vivo for treatment and prevention of disease, or in vitro for generation of lesion- or disease- specific cytotoxic T lymphocytes (CTLs) . Arming treated cells in vitro provides the advantage of being able to use a bridging directed to any antigen on the target cell.
When used for treatment or immunization of a patient, in vitro treated and armed cells may be administered to the patient using a variety of methods known to those skilled in the art. In a particular embodiment, described more fully in the examples which follow, in vitro treated and armed cells are administered subcutaneously. In another embodiment, the treated and armed cells are administered by direct intralesion injection, an administration route that may provide advantages over subcutaneous administration in certain circumstances (for example, where the lesion to be treated is not well vascularized, is inaccessible for biopsy, or cannot be disrupted without creating further risk to the patient) . In a further embodiment, the treated and armed cells are administered by injection into the lymph nodes. This method of administration requires fewer treated and armed cells than may typically be required using other routes of administration. Such intralymph administration may be preferred in situations where only limited autologous tissue can be obtained from a lesion using thin needle biopsy techniques (i.e., inaccessible/inoperable cancers). Moreover, intralymph administration is likely to enhance the interaction between the cellular vaccine and T cells given the large number of T cells within lymph nodes. Applicant's initial experimental data indicates that a single intralymph injection of as few as 1 X IO4 cellular cancer vaccine cells, prepared using the method of the invention, can induce an effective immune response against parenteral tumor cell challenge and can cure established tumors. The therapeutic efficacy of this method of administration appears
equivalent to that achieved using 100-times more cells administered subcutaneously.
In a specific embodiment of the method of the invention, Bi- MAbs that react with CD28 are used as a bispecific bridging substance. As briefly discussed in Section 2, supra, B7 interacts with both CD28 and CTLA-4 on T cells. Under certain circumstances, the B7-CTLA-4 interaction generates a negative signal which prevents T cell activation. Thus, by immunizing with cells coated with Bi-MAbs specific for CD28, the interactions between B7 on such cells and CTLA-4 (or other T cell activation down-regulating molecules) is minimized and/or by¬ passed. In addition, Bi-MAbs reactive with other costimulatory T cell surface molecules (i.e., CD2, CD48) may also be used in the practice of the method of the invention. Furthermore, more powerful costimulation may be achieved by using a multiplicity of Bi-MAbs having specificity for various T cell costimulators.
Bridging substances may be prepared using well known technologies. As shown in the examples which follow, Bi-MAbs may be used effectively as the bridging substance. Such Bi-MAbs may be generated using methods well known in the art, such as, for example, those described in Section 6.2., infra, and as described in the references cited therein. Bi-MAbs containing multiple T cell costimulatory molecule binding sites may be prepared by chemical linkage in order to provide a means for generating multiple costimulatory activation circuits.
In addition to Bi-MAbs, molecules engineered to contain functional binding sites specific for both the antigen(s) of the
target cell(s) and the T cell costimulatory molecule(s) may be used as the bridging substance in the practice of the method of the invention. Such molecules may, for example, comprise proteins, other macromolecules, and polymers engineered to contain the desired binding sites, and may be prepared by using genetic engineering technologies, synthetic technologies, or by chemical linkage of component polypeptides, polymers, and/or other macromolecules. The binding site components of such bridging substances may comprise, for example, Fab2 antibody fragments, antibody binding sites, natural or engineered ligands, or other factors reactive with the target cell antigen(s) and T cell costimulatory molecule(s) .
The bridging substance may be administered to a patient in vivo using a pharmaceutically acceptable carrier or a variety of drug delivery systems well known in the art. As an example, for cancer immunotherapy, a combination of the cytokines TNF-α and IFN-γ and an anti-CD28 Bi-MAb may be formulated within a controlled release preparation which is administered to the patient by directly injecting the preparation into the lymph nodes or into the tumor itself.
The method of the invention is particularly useful in treating cancers. This aspect of the invention is more fully described by way of the examples presented in Section 6., infra. The data presented in the examples indicate that strongly immunogenic tumor cells can be generated using the two-step method of the invention, comprising (1) in vitro treatment of autologous tumor cells with a combination of γ- interferon (IFN-
y) and tumor necrosis factor-α (TNF-α) , and (2) pre-incubation with a Bi-MAb specific for both antigen on tumor cells and CD28 on T cells. The resulting modified tumor cells are able to act as a cellular vaccine that elicits CTL-mediated immunity which can both prevent and cure established tumors.
In particular, the studies described in the examples which follow show that cytokine-treated, anti-CD28 Bi-MAb-armed hepatoma cells induce protective immunity against parental tumor cell challenge and, moreover, cure established gross hepatomas in mice. In addition, the studies described in Section 6.7., infra, show that the method of the invention also induces protective immunity against lymphoma and colon carcinoma.
Different routes of administration, or combinations thereof, may be preferred when treating different cancers or other diseases using the cellular vaccines of the invention. As illustrated by the study briefly described in Section 6.4., immunization with cytokine-treated (and un-armed) cells followed by intravenous administration of an anti-CD28 Bi-MAb induces some anti-tumor immunity in the hepatoma model system. In comparison, as shown by the results of the studies described in Sections 6.5. and 6.6., infra, the administration of cells treated with cytokines in vitro and armed with Bi-MAbs in vitro induces uniform tumor immunity and cures established hepatomas. It is possible that insufficient localization of the Bi-MAbs to the tumor tissue following intravenous injection in the former case is responsible for the difference in therapeutic efficacy.
Individuals may be immunized against a variety of diseases with cytokine-treated, anti-CD28 Bi-MAb-armed autologous cells, thereby providing the individual's immune system with a signal sufficient to activate T cells and confer protective immunity. Similarly, individuals may be treated for a variety of diseases by administering cytokine-treated, anti-CD28 Bi-MAb-armed autologous cells of the disease or lesion, thereby providing the individual's immune system with a signal sufficient to activate T cells and induce a cytotoxic T lymphocyte response. In both cases, BI-MAbs with a specificity for other T cell costimulatory molecules may be used to arm the treated cells with a means to physically bridge to T cells in vivo.
In addition to MHC class I, ICAM-1, ICAM-2 and VCAM-1 molecules, treatment with cytokines may enhance tumor antigen processing by tumor cells, and may induce the expression of other cell surface molecules essential for T cell activation. The combination of cytokine treated hepa 1-6 cells and immobilized anti-CD28 MAb fails to stimulate splenic T cells in vitro or to induce anti-tumor immunity in vivo in applicant's model system. This suggests that the signal delivered by the interaction between CD28 and anti-CD28 MAb is not sufficient in itself to induce T cell activation.
In contrast, a strongly immunogenic response is obtained when cytokine treated tumor cells armed with anti-CD28 Bi-MAb in vitro interact with CD28 on T cells, indicating that a physical bridging function is an important component of the activation process.
In addition, the observation that cytokine treated, B7 transfected hepa 1-6 cells were not able to activate splenic T cells in vitro (Section 6.2., infra) is consistent with the recent finding that B7 may interact with CTLA-4 to deliver a negative regulatory signal, and provides a strong rationale for using anti-CD28 Bi-MAbs to physically link the antigen presenting cell specifically to CD28 molecules for T cell activation.
The invention provides an effective alternative to gene transfer and tumor:APC engineering for the development of cellular vaccines. In particular embodiments of the invention, described in the following examples, the attachment of Bi-MAbs to tumor or other target cells takes place in vitro. Accordingly, the antigens on such cells need not be unique to those cells. Essentially, any antigen may be targeted. Bi-MAbs can be produced by linking anti-CD28 MAbs to Mabs that recognize any antigen expressed on the tumor or other target cell, including antigens which are also expressed on large populations of cells in the individual to be treated (i.e., lymphocytes) . This approach may be particularly useful in situations where Mabs to tumor specific antigens are not available.
EXAMPLE 6.1
CYTOKINE INDUCED EXPRESSION OF ADHESION
AND MHC MOLECULES ON HEPA 1-6 CELLS IN VITRO
Hepa 1-6 is a chemically induced hepatoma originating in a C57BL/6 mouse (G. J. Darlington et al . , 1980, J. Natl. Cancer Inst . 6_4_: 809) . Cells derived from this tumor grow rapidly and form subcutaneous nodules in syngeneic animals. Hepa 1-6 cells
lack both MHC class I and B7 molecules on their cell surfaces and do not induce a host immune response even when transfected with genes encoding the B7-1 or B7-2 molecule.
The conditions and cytokines most optimal for the amplification of activation signals on hepa 1-6 cells were determined as follows. One ml of Hepa 1-6 cells was plated into 24 well tissue culture plates at a concentration of 2 x IO6 cells / ml and incubated with either IFN-γ, 100 U, or TNF-α, 50 U, or a combination of IFN-γ and TNF-α at these same concentrations in complete RPMI-1640 medium supplemented with 10 % fetal calf serum, 2mM glutamine, lx non-essential amino acid and 1 mM sodium pyruvate for 48 hr at 37°C. Hepa 1-6 cells incubated similarly but in medium alone were used as control.
Cells were washed with phosphate-buffered saline (PBS) and stained with rat monoclonal antibodies to mouse MHC class I (Ml/42), MHC class II (M5/114), CD44 (KM81) (ATCC), ICAM-1 (HA58) , ICAM-2 (3C4) and VCAM-1 (51-10C9) ( PharMingen, San Diego, California) . To stain for mouse B7-1 (CD80) and B7-2 (CD86) , we used CTLA4-Ig, a soluble fusion protein containing the variable domain of the human CTLA4 protein and the hinge, CH2, and CH3 domains of the human IgGl constant region (Y. J. Guo et al., 1994, Science 263: 518; C. Caux et al. , 1994, J. Exp. Med. 180: 1841; E. Murphy et al. , 1994, J. Exp. Med. 180: 223; R. Seder et al. , 1994, J. Exp. Med. Hi: 299; B. Blazar et al. , 1994, Blood £3_: 3815; K. Hathcock et al. , 1993, Science 262: 905; P Linsley et al. , 1991, J. Exp. Med. 124.: 561).
Cells were incubated with the antibodies or chimeric
protein for 40 minutes on ice. A rat antibody to mouse CD3 (YCD3) and a soluble human CD44-Ig chimeric protein were used as a negative controls. Cells were washed three times. Fluorescent isothiocyanate (FITC) -conjugated goat antibody to rat Ig or FITC- labeled rabbit antibody to human Ig was added for an additional 40 minutes on ice. Samples were then washed, fixed and analyzed in a FACScan (Becton Dickinson, San Jose, California) . The mean fluorescent intensity in the negative control group (medium alone) was at background level except for ICAM-1. Hepa 1-6 cells incubated with a combination of interferon (IFN-γ) and tumor necrosis factor (TNF-α) showed expression of MHC class I, intercellular adhesion molecule 2 (ICAM-2) and vascular adhesion molecule 1 (VCAM-1) , and showed significantly enhanced expression of intercellular adhesion molecule 1 (ICAM-1) (FIG. 1) . This pattern of expression was maintained for more than three days in vitro after removing cytokines from the medium. However, the cytokine treated hepa 1-6 cells (CT-hepa 1- 6) were still able to form tumors in syngeneic animals. It was assumed that this may be because the cells were deficient in providing a CD28 mediated costimulatory signal due to absence in expression of B7.
EXAMPLE 6.2 STIMULATION AND PROLIFERATION OF SYNGENIC SPLENIC T-CELLS INDUCED BY CYTOKINE TREATED
HEPA 1-6 CELLS AND ANTI-CD28 Bi-MAb IN VITRO
The following example demonstrates that cytokine activated Hepa 1-6 cells in combination with Bi-MAbs to CD28 and tumor cell
antigens stimulate proliferation of splenic T cells in vitro, indicating that such Bi-MAbs can provide a CD28 costimulatory signal. Three Bi-MAbs, CD28:gp55, CD28:gp95, and CD28:gp210, each with one binding specificity for the CD28 molecule on T cells and a second binding specificity for one of three glycoproteins expressed on tumor cell surfaces, were prepared and used as follows.
For preparation of Mabs and Bi-MAbs, Wistar rats were immunized with 2 x IO7 Hepa 1-6 cells in CFA. Following three additional boosts with the same cells in ICFA over an 8 week period, spleen cells from immunized rats were fused with YB2/0 rat myelomas as previously described (J. Alan & T. Robin, in: Immunochemistry in Practice, Chapter 2 (Blackwell, New York, 2d ed. 1988) ) . More than twenty Ig-producing hybridomas were selected by immunofluorescent staining. Three antibodies reacted with hepa 1-6 cells by flow cytometry analysis. These Mabs separately recognized a 55 Kd, 95 Kd or 210 Kd glycoprotein expressed on most tumor cells as determined by immunoprecipitation. The Mabs were designated as anti-gp55, anti-gp95 and anti-gp210 respectively. Anti-mouse CD28 Mabs were generated by first immunizing Wistar rats with a mouse T cell hybridoma cell line expressing high levels of CD28 antigen on the cell surface. After cell fusion, hybridomas producing anti-CD28 MAb were selected with immunofluorscent analysis by FACScan. Anti-CD28 Mabs were further characterized and confirmed by immunoprecipitation and T cell proliferation and IL-2 production assays. Hybridoma producing anti-mouse CD18 used to generate
CD18:gp55 Bi-MAb was purchased from ATCC. All Mabs used in these experiments were purified by passage of ascites from nude mice over a protein G column.
Bi-MAbs were produced from these Mabs as previously described (J. A. MacLean et al., 1993, J. Immunol. 150: 1619; L. K. Gilliland et al. , 1988, Proc. Natl. Acad. Sci. USA £5_: 7719; C. Bode et al., 1989, J. Biol. Chem. 2£4: 944).
Normal splenic T cells were purified by nylon wool column. Purified T cells (5 x 106/ well) were co-cultured in complete RPMI-1640 medium at 37°C for 96 hours with 5 x IO5 irradiated
(5000 roentgens) cytokine treated (as described in Section 6.1., supra) or untreated hepa 1-6 cells in the presence or absence of CD28:gp55, CD28:gp95 or CD28:gp210 Bi-MAb. A CD18:gp55 Bi-MAb that bridges CD18 on T cells to gp55 on tumor cells and a mixture of parental CD28 plus gp55 Mabs were used as controls. Cytokine treated or untreated hepa 1-6 cells transfected with B7 gene and expressing high level of B7 molecules on cell surfaces were also used as a control. The percentage of CD3+CD8+CD25+ T cells (mean V SD) was determined by three color analysis in FACScan using Cy- Chrom™ labeled anti-CD3, PE-labeled anti-CD8 and FITC-conjugated anti-CD25 antibodies (PharMingen, San Diego, California) .
Each of the Bi-MAbs was tested both in vitro and in vivo for its ability in combination with cytokine treatment of hepa 1-6 cells to activate tumor specific CTLs. Mouse splenic cells were cocultured with either cytokine treated or untreated hepa 1-6 cells in the presence of purified anti-CD28 Bi-MAb or control antibody, 50 mg/ml each, at 37°C for 9 days.
The results presented in FIG. 2 indicate that the combination of cytokine treated tumor cells and any one of the three anti-CD28 Bi-MAbs significantly stimulated splenic T cell proliferation. No stimulation was obtained in the absence of either anti- CD28 Bi-MAbs or the cytokine treated autologous tumor cells. Interestingly, hepa 1-6 cells transfected with, and expressing high levels of B7, were not effective in stimulating naive T cells in vitro when treated with the cytokines in similar manner. The majority of lymphocytes generated by this approach were CD3+CD8+CD25+ T cells.
EXAMPLE 6.3 IN VITRO CYTOTOXICITY OF CTLa GENERATED BY CYTOKINE TREATED HEPA 1-6 TUMOR CELLS
IN COMBINATION WITH ANTI-CD28 Bi-MAbs
Cytotoxicity of CTLs generated by in vitro priming of naive splenic T cells with cytokine treated hepa 1-6 cells in combination with anti-CD28 Bi-MAbs or control MAb was established as follows. Nylon wool-enriched naive splenic T cells (5 x 106/well) were first stimulated in vitro by incubation with 5 x IO5 irradiated (5000 roentgens) cytokine treated hepa 1-6 cells (as described in Section 6.1., supra) in combination with anti- CD28 Bi-MAbs, control antibodies or irradiated B7+ hepa 1-6 alone at 37°C for 9 days. y-irradiated naive splenic cells (5 x IO6) were added into cultures as feeder cells. At the 3rd and 6th day after stimulation, 2 ml of complete RPMI-1640 medium containing recombinant human IL-2 (20 U) were added into each culture well
separately.
Cytotoxicity of CTLs toward syngeneic, allogenic tumor cells and a NK sensitive YAC-1 cell line was determined in a standard 4 hour 51Cr release assay. Results from three experiments are shown in FIG. 3 as the percentage of 51Cr release at 1:20 E:T ratio as measure of tumor cell lysis (mean VSD) . These results show that CTLs generated as described herein have cytolytic activity specific to autologous tumor cells.
EXAMPLE 6.4
EFFECT OF INTRAVENOUSLY ADMINISTERED ANTI-CD28 Bi-MAbs ON TUMORIGENICITY OF CYTOKINE TREATED HEPA 1-6 CELLS
Mice injected with cytokine treated hepa 1-6 cells followed by intravenous administration of anti-CD28 :gp55 Bi-MAb at a dose of 100 ug on day 1, 2 and 4, experienced delayed tumor formation and 40 percent of these mice (8/20) had tumor regression.
Animals injected with a combination of parental hepa 1-6 cells and anti-CD28 Bi-MAb or a combination of CT-hepa 1-6 cells and control antibody all developed tumors and died within 60 days after the inoculation of tumor cells. Immunohistological studies at 24, 48, and 72 hr after injection of the Bi-MAbs showed that the Bi-MAbs were widely distributed in lungs, liver and kidney in addition to tumor tissue.
EXAMPLE 6.5 INDUCTION OF PROTECTIVE IMMUNITY IN VIVO WITH CYTOKINE TREATED HEPA 1-6 TUMOR CELLS ARMED WITH ANTI-CD28 Bi-MAbs
Tumor cells were first treated in vitro with a combination
of IFN-γ, 100 U, and TNF-α, 50 U, in RPMI-1640 medium with 10% fetal calf serum at 37°C, 5% C02 for 48 hours. Cells were then washed with Phosphate-Buffered Saline, PH 7.4 (PBS) x 3 at 20°C and incubated with anti-CD28 Bi-MAbs at a concentration of 50 ug/ml on ice for 45 min as described in Section 6.1., supra. After an additional incubation in an equal volume of 30% polyethylene glycol (PEG) in RPMI-1640 for 60 minutes at 4°C, the cells were washed x3 as described above and suspended in a final concentration of 1-2 x IO7 / ml PBS. To arm cells with Bi-MAbs or Mabs, cytokine treated or untreated parental tumor cells were pre-incubated with respective antibodies for 45 minutes.
Five groups of C57BL/6 mice, 5 per group, were immunized subcutaneously with 1 x IO6 cytokine treated hepa 1-6 cells armed with CD28:gp55, CD28:gp95, CD28:gp 210 or a control Bi-MAb CD18:gp55, or with 1 x IO6 untreated hepa 1-6 cells armed with CD28:gp55 Bi-MAb. After two weeks, mice in each of the groups were challenged with 2.5 x IO6 parental hepa 1-6 cells injected subcutaneously.
Cytokine treated hepa 1-6 tumor cells (CT-hepa 1-6) pre- incubated/armed with anti-CD28 Bi-MAbs completely lost their ability to form tumors in syngeneic mice, whereas cytokine treated hepa 1-6 cells pre-incubated/armed with control antibodies retained their tumor forming capacity. The results of the immunization experiment are shown in FIG. 4. Mice immunized with CT-hepa 1-6 cells armed with each of the CD28/tumor antigen Bi-MAbs developed protective immunity against challenge with parental tumor cells, and all of these animals remained tumor-
free for 120 days after such challenge (FIG. 4) . In contrast, all mice injected subcutaneously with either untreated Hepa 1-6 cells armed with anti-CD28 Bi-MAbs or CT-hepa 1-6 cells armed with the control antibody CD18:gp55 developed tumors and died within 50 days following challenge with the parental hepa 1-6 cells (FIG.4) . This experiment was repeated twice with comparable results.
EXAMPLE 6.6 APPLICATION OF THE METHOD OF THE INVENTION TO THE HEPATOMA CANCER
SXSHMj CURE OF ESTABLISHED HEPAOTOMAS WITH CYTOKINE TREATED,
Bi-MAb-ARMED HEPA 1-6 CELLS
To establish that immunization with CT-hepa 1-6 cells armed with anti-CD28 Bi-MAbs can cure established hepatomas, the following three studies were performed, each of which indicates that the therapeutic administration of Bi-MAb-armed, cytokine treated hepa 1-6 cells is an effective therapy for hepatoma. In the first study, forty mice were inoculated subcutaneously with 2 x IO6 wild type hepa 1-6 cells. Fourteen days later, after the development of microscopic tumors, the mice were divided into four groups of ten each. The groups were treated subcutaneously with 2 x IO6 cytokine treated or untreated hepa 1-6 cell armed with either the CD28:gp55 Bi-MAb or a control CD18:gp55 Bi-MAb.
The results of this study are shown in FIG. 5. All mice in the group treated with CT-Hepa 1-6 cells armed with anti-CD28 Bi- MAb survived for more than 100 days (FIG 5) . In contrast, all mice in the group treated with control Bi-MAb-armed/cytokine
treated hepa 1-6 cells, and all mice in the groups treated with untreated hepa 1-6 cells armed with the CD28:gp55 Bi-MAb or the CD18:gp55 control Bi-MAb, died within about 40 days (FIG. 5). This experiment was repeated twice with comparable results. In the second study, five groups of five mice each were injected subcutaneously with 1 x IO6 hepa 1-6 cells. After four weeks, mice bearing tumors 6-8 mm (in the greatest dimension) were injected subcutaneously with 1 x IO6 cytokine treated hepa 1-6 cells armed with the CD28:gp55, CD28:gp95 or CD28:gp210 Bi- MAbs, respectively, and then injected subcutaneously with a boost of the Bi-MAb-armed/cytokine treated hepa 1-6 cells at the same dose 7 days thereafter. Cells pre-incubated with CD18:gp55 or mixed with both anti-CD28 and anti-gp55 parental Mabs (CD28+gp55) at a concentration of 50 ug each were used as controls. Tumor size was periodically measured.
The results of this study are shown in FIG. 6. Hepatomas in the mice treated with the CD28:gp55, CD28:gp95 and CD28:gp210 Bi- MAbs regressed to undetectable size within about 40 days (FIG. 6) . In contrast, hepatomas in the mice treated with the CT-hepa 1-6 cells pre-incubated with either control Bi-MAb or MAb more than doubled in size within the same period, and all of these mice within that period (FIG. 6) . This experiment was repeated three times with comparable results.
In the third study, γ~irradiated Bi-MAb armed tumor cells were used as the vaccine. Three groups of five mice were inoculated subcutaneously with 1 x IO6 hepa 1-6 cells. After two weeks, mice were then injected subcutaneously either with 1 x IO6
γ-irradiated, cytokine treated hepa 1-6 cells armed with CD28:gp55 Bi-MAb, or with a combination of γ-irradiated, cytokine treated hepa 1-6 cells plus a mixture of parental anti-CD28 and anti-gp55 Mabs, or with 1 x IO6 γ-irradiated hepa 1-6 alone. The results of this study, shown in FIG. 7, are similar to the results obtained in the second study described above. Only the mice treated with the y-irradiated, cytokine treated hepa 1-6 cells armed with CD28:gp55 Bi-MAb survived (for more than 100 days) . All mice in the other two groups died within 40 days of treatment .
Upon examination, tumor tissue from mice first injected with the parental tumor cells and then given cytokine treated autologous tumor cells pre-incubated with anti-CD28 Bi-MAb showed marked inflammatory responses with abundant lymphocyte infiltration. In accordance with in vitro stimulation data, the majority of the infiltrating lymphocytes were CD3+CD8+ CD25+ T cells, as determined by immunofluorescent staining of tissue sections with rat anti-mouse CD3, CD8 and CD25 MAbs. There was no local immune response in mice injected either with untreated tumor cells armed with anti-CD28 Bi-MAb or with cytokine treated tumor cells armed with control Bi-MAbs.
To further investigate if the induced immunity was mediated by CTLs, mice were depleted of CD8+ T cells by antibody treatment before or after immunization. Depletion of CD8+ T cells either before or after immunization abrogated the ability of the cellular vaccine to elicit anti-tumor immunity in vivo.
EXAMPLE 6 .7
APPLICATION OF THE METHOD OF THE INVENTION TO ADDITIONAL CANCER
SYSTEMS; INDUCTION OF PROTECTIVE IMMUNITY AGAINST LYMPHOMA AND
COLON CARCINOMA USING CYTOKINE TREATED. Bi-MAb-ARMED CANCER CELLS
The immunogenicity of cytokine treated, autologous tumor cells pre-incubated with anti-CD28 Bi-MAbs was tested in two additional cancer systems, EL-4 lymphoma and SMCC-1 colon carcinoma. The EL-4 lymphoma becomes immunogenic when transfected with the B7 gene. In contrast, SMCC-1 colon carcinoma remains non- immunogenic even after transfection with the B7 gene. Both of these cell lines grow rapidly and develop subcutaneous tumors in syngenic C57 BL/6 mice (see, for example, Li et al. , 1996, J. Exp. Med. 180: 211) . Both of these cell lines express the gp55 antigen on their cell surfaces. Accordingly, the anti-CD28 :gp55 Bi-MAb described in the previous examples was also used in these studies.
Three groups of mice were immunized subcutaneously with 1 x IO6 cytokine treated, CD28:gp55 Bi-MAb-armed, hepa 1-6, EL-4 or SMCC-1 tumor cells respectively.
After two weeks, mice immunized with the modified hepa 1-6 cells were divided into three groups and challenged by a subcutaneous injection with 1 x IO6 hepa 1-6 cells, SMCC-1 cells or EL-4 cells respectively.
The mice immunized with the cytokine treated, CD28:gp55 Bi- MAb-armed SMCC-1 cells were divided into two groups. One group was challenged by subcutaneous inoculation with 1 x IO6 SMCC-1 cells. The other group was challenged by subcutaneous
inoculations of EL-4 cells and 1 x IO6 hepa 1-6 cells into the left and right flanks of mice, respectively.
Similarly, the mice immunized with the cytokine treated, CD28:gp55 Bi-MAb-armed EL-4 cells were divided into two groups which were challenged with either EL-4 cells alone or with both SMCC-1 and hepa 1-6 cells.
The results of this study, presented in Table I below, were repeated twice with identical results.
TABLE I
Specificity of the immune responses elicited by cytokine treated and anti-CD28 Bi-MAb armed tumor cells,
Immunization with cytokine treated EL-4 (CT-EL-4) or cytokine treated SMCC-1 (CT-SMCC-1) tumor cells armed with the anti-CD28 :gp55 Bi-MAb elicited anti-tumor immunity against autologous parental tumor in all animals (Table 1) .
The elicited immunity in all three experimental groups was tumor-specific. For example, immunization with CT-hepa 1-6 cells armed with anti-CD28 Bi-MAb did not inhibit growth of syngeneic
EL-4 or SMCC-1 tumors in vivo (Table 1) . Interestingly, in the absence of treatment with cytokines, the parental EL-4 cells expressed high levels of MHC class I at cell surfaces, yet when pre-incubated with anti-CD28 :gp55 Bi-MAb, they were still not able to induce protective immunity. In addition, CTLs from mice immunized with cytokine treated autologous tumor cells armed with anti-CD28 Bi-MAbs specifically lysed the parental tumor cells but not other tumor cells in vitro.
EXAMPLE 6.8
INDUCTION OF CELLULAR IMMUNITY BY TUMORS ARMED WITH MULTIVALENT
BRIDGE MOLECULES
The above data showed that SMCC-1, EL-4 and Hepal-6 cells became more immunogenic after treatment in vi tro with a combination of cytokines and anti-CD28 bispecific monoclonal antibody. The modified tumor cells were able to elicit anti-tumor specific immunity that were both preventive and curative. The following data showed that EL-4 and SMCC-1 cells were also effective for eliciting preventive and curative antitumor immunity in syngenic animals without cytokine treatment when these cells were precoated with two different bispecific monoclonal antibodies (bi-Mabs) , one specific for CD28 and another specific for 4-IBB.
The cells were coated in vi tro with anti-gp55 :anti-CD28 and anti-gpll5 :anti-4-lBB bi-Mabs in a concentration of 50 ug/ml on ice for 45 min. After fixed with PEG and washed for three times,
the tumor cells coated with the two different bi-Mabs were subcutaneously injected into syngenic animals at different doses. Two weeks later, the immunized animals were challenged with parental tumor cells and tumor formation rate was observed (Table ID.
Table II.Comparison of the efficacy of immunogenic tumor cells modified with different process in vi tro on eliciting preventive antitumor immunity in vivo
Xmmuiύzation Dose Chall enge Tumor Formation
Irradiated EL-4 Wt lxlO6 lxlO6 EL- 4 Wt 100%
Irradiated CT-EL-4Wt lxlO6 lxlO6 EL-4 Wt 100%
Irradiated EL-4 coated CD28BiMab 1x10s 1x10s EL- 4 wt 50% Irradiated CT-EL-4 coated CD28BiMab lxlO6 lxlO6 EL-4 wt 0% lxlO5 lxlO6 EL-4 wt 20%
5xl04 lxlO6 EL-4 wt 60%
Irradiated EL-4 Wt coated anti-CD28£canti-4-lBB BiMabs lxlO6 lxlO6 EL-4 wt 0% lxl05 lxlO6 EL-4 wt 0%
In curative experiments, syngenic animals were first inoculated subcutaneously with 2xl06 parental tumor cells. After two to four weeks, the tumor bearing animals were injected with the modified tumor cells. The mean survival time was monitored (Table III) .
Table IIX . Comparison of the efficacy of immunogenic tumor vaccines armed with monovalent or multivalent bi- specific Mabs on eliciting curative an ti tumor immunity in vivo
Tumors Vaccination Dose Animal
SMCC-l SMCC-lWt lxlO6 0%
SMCC-l CT-SMCC-1+CD28 BiMabs lxl06 100%
5xl05 30%
SMCC-l SMCC-1+CD28 & 4-IBB BiMabs lxlO6 100%
SxlO5 80%
SMCC-l SMCC-1+CD28& 4-1BB BiMabs
(multivalent BiMabs) 1X106 100%
5xl05 100%
1X1P5 60%
* 60 day survival rate after tumor vaccine treatment .
EXAMPLE 6 . 9 GENERATION OF CELLULAR IMMUNITY AGAINST VIRUS INFECTED CELLS
Primary liver cells were obtained from clinical biopsy laboratory and cultured in hepatocellular media . Autologous peripheral blood lymphocytes were obtained from same patients during operation and cultured in complete RPMI -1640 medium supplemented with 5% human AB serum and 5% fetal calf serum, 20 iu/ml rh- IL- 2 .
Liver cells were infected by E1B deleted Adenovirus as reported previously . Virus infection was confirmed by RT-PCR and histological examination .
Infected liver cells were then treated in vi tro with ( 1 ) cytokines alone , ( 2 ) BiMabs alone , or ( 3 ) cytokine + bispecific Mabs . The modified virus - infected liver cells were irradiated at
a dose of 5000R and were then co-cultured with autologous PBL in complete RPMI-1640 medium as reported previously.
The cytotoxicity of the CTLs generated by the unmodified and the modified liver cells was determined with a standard 4 h 51Cr release assay.
Table IV.Generation of cytotoxic T cells in vitro by stimulating autologous peripheral blood lymphocytes with virus-infected human fetal liver cells pretreated with a combination of INF-γ and TNF-α and coated with anti-CD28 bispecific monoclonal antibody
Target cells Treatment Effectors E:T Ratio Cytotoxicity
Liver cells None PBL 1:50 -3%
Liver cells Cytokines PBL 1:50 -3%
Liver cells BiMabs PBL 1:50 -3%
Liver cells Cyto+BiMab PBL 1:50 -3%
Ad-Liver cells None PBL 1:50 -3%
Ad-Liver cells Cytokines PBL 1:50 -5%
Ad-Liver cells BiMabs PBL 1:50 -13%
Ad-Liver cells Cyto+biMabs PBL 1:50 -20%
Ad-Liver cells biMabs (Multivalent*)
PBL 1:50 -40%
Ad-Liver cells Cyto+biMabs (Multivalent*)
EBL 1:50 ~4Q%
•Anti-Gpll5 :Anti-CD28 bispecific monoclonal antibody was generated by chemical linking several anti-CD28 and anti-Gpll5 monoclonal antibodies together and purified by sequential affinity columns , one specific binding gp- 115 and another for CD28 monoclonal antibody specifically.
The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single
illustrations of individual aspects of the invention, and any which are functionally equivalent are within the scope of the invention. Various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description, and are similarly intended to fall within the scope of the invention. For example, Guo et al., Nature Medicine, vol. 4:1-5, (April, 1997) provide examples and references. All publications referenced are incorporated by reference herein, including drawings, nucleic acid sequences and amino acid sequences listed in each publications. All the compounds disclosed and referred to in the publications mentioned above are incorporated by reference herein, including those compounds disclosed and referred to in articles cited by the publications mentioned above.
Other embodiments of this invention are disclosed in the following claims.
Claims (49)
1. An immunogenic composition for administration to a patient mammal having diseased cells, comprising:
(a) an autologous target diseased cell which expresses one or more primary and costimulatory T cell activation molecules at a level higher than said diseased cells in said patient mammal; and
(b) a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal, wherein said bridge molecule is attached to said target diseased cell.
2. The composition of claim 1, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
3. The composition of claim 1 which is isolated, enriched or purified.
4. The composition of claim 1, wherein said one or more primary and costimulatory T cell activation molecules are selected from the group consisting of MHC class I, ICAM-1, ICAM-2, VCAM-1, B7-1, and B7-2.
5. The composition of claim 1, wherein said one or more primary and costimulatory T cell activation molecules are expressed from heterologous nucleic acids introduced into said target diseased cell.
6. The composition of claim 1, wherein said target diseased cell is treated with one or more cytokines in vi tro to increase the expression of said one or more primary and costimulatory T cell activation molecules.
7. The composition of claim 6, wherein said target diseased cell is treated with IFN-γ, TNF-α, or both.
8. The composition of claim 1, wherein said bridge molecule comprises a binding site for CD28 or 4-IBB on the surface of T cells.
9. The composition of claim 2, wherein said antigens are selected from the group consisting of LDL receptor, gp55, gp95, gpll5, gp210, CD44, ICAM-1, ICAM-2, collagen and fibronectin receptor, transferrin receptors, Fc receptor, and cytokine receptors.
10. The composition of claim 1, wherein said bridge molecule is an antibody with specific binding affinity to said one or more costimulatory molecules on the surface of T cells.
11. The composition of claim 2, wherein said bridge molecule is attached to said one or more antigens on the surface of said target diseased cell by covalent bond.
12. The composition of claim 1, wherein said target diseased cell is a tumor cell.
13. The composition of claim 12, wherein said tumor cell is selected from the group consisting of hepatoma, lung cancer, gastric cancer, colorectal carcinoma, renal carcinoma, head and neck cancers, sarcoma, lymphoma, leukemia, brain tumors, osteosarcoma, blade carcinoma, myeloma, melanoma, breast cancer, prostate cancer, ovarian cancer, and pancreas carcinoma.
14. The composition of claim 1, wherein said target diseased cell is infected with a virus.
15. The composition of claim 14, wherein said virus is selected from the group consisting of HIV, HAV, HBV, HCV, HDV, EBV, HPV, and HLV.
16. An immunogenic composition for administration to a patient mammal having diseased cells, comprising:
(a) an autologous target diseased cell; and (b) two or more bridge molecules each comprising a binding site for a different costimulatory molecule on the surface of T cells, wherein said bridge molecules are attached to the surface of said target diseased cell.
17. The immunogenic composition of claim 16 wherein said two or more bridge molecules each comprising a binding site for a different antigen on the surface of said target diseased cell.
18. An immunogenic composition for administration to a patient mammal having diseased cells, comprising: (a) an autologous target diseased cell; and
(b) a bridge molecule comprising two or more different binding sites for two or more different costimulatory molecules on the surface of T cells, wherein said bridge molecule is attached to the surface of said target diseased cell.
19. The composition of claim 18, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
20. A pharmaceutical composition comprising:
(a) a pharmaceutically effective amount of a cytokine capable of increasing the level of one or more primary and costimulatory T cell activation molecules in tumor cells of a patient mammal; (b) a pharmaceutically effective amount of a bridge molecule comprising a binding site for an antigen on the surface of said tumor cells and a binding site for a costimulatory molecules on the surface of T cells; and (c) a pharmaceutically acceptable carrier.
21. A pharmaceutical composition for administration to a patient mammal having diseased cells, comprising:
(a) a pharmaceutically effective amount of an autologous target diseased cell having attached thereto one or more bridge molecules each comprising a binding site for a costimulatory molecule on the surface of T cells in said patient mammal; and
(b) a pharmaceutically acceptable carrier.
22. The composition of claim 21, wherein said one or more bridge molecules each further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and are attached to said target diseased cell at said antigens.
23. A method of preparing an immunogenic composition for administration into a patient mammal having diseased cells, comprising the steps of : (a) providing an autologous target diseased cell;
(b) treating said target diseased cell to increase the levels of one or more primary and costimulatory T cell activation molecules;
(c) providing a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal; and (d) attaching said bridge molecule to said target diseased cell; wherein said steps (c) and (d) are performed either before or after said step (b) .
24. The method of claim 23, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
25. The method of claim 23, wherein said one or more primary and costimulatory T cell activation molecules are selected from the group consisting of MHC class I, ICAM-1, ICAM-2, VCAM-1, B7-1, and B7-2.
26. The method of claim 23, wherein said one or more primary and costimulatory T cell activation molecules are expressed from heterologous nucleic acids introduced into said target diseased cell.
27. The method of claim 23, wherein said target diseased cell is treated with one or more cytokines in vi tro to increase the expression of said one or more primary and costimulatory T cell activation molecules.
28. The method of claim 27, wherein said target diseased cell is treated with IFN-γ, TNF-α, or both.
29. The method of claim 23, wherein said bridge molecule comprises a binding site for CD28 or 4-IBB on the surface of T cells.
30. The method of claim 24, wherein said antigen is selected from the group consisting of LDL receptor, gp55, gp95, gpll5, gp210, CD44, ICAM-1, ICAM-2, collagen and fibronectin receptor, transferrin receptors, Fc receptor, and cytokine receptors.
31. The method of claim 23, wherein said bridge molecule is an antibody with specific binding affinity to said one or more costimulatory molecules on the surface of T cells.
32. The method of claim 24, wherein said bridge molecule is attached to said one or more antigens on the surface of said target diseased cell by covalent bond.
33. A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the step of administering to said patient mammal a pharmaceutically effective amount of an immunogenic composition which comprises:
(a) an autologous target diseased cell which expresses one or more primary and costimulatory T cell activation molecules at a level higher than said diseased cells in said patient mammal;
(b) a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal, wherein said bridge molecule is attached to said target diseased cell.
34. The method of claim 33, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
35. The method of claim 33 wherein said immunogenic composition is prepared in vi tro .
36. A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of :
(a) providing an autologous target diseased cell; (b) treating said target diseased cell to increase the levels of one or more primary and costimulatory T cell activation molecules in said target diseased cell; (c) providing a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal;
(d) attaching said bridge molecule to said target diseased cell; and
(e) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecule attached thereto and administering said collection to said patient mammal; wherein said steps (c) and (d) are performed either before or after said step (b) .
37. The method of claim 36, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
38. The method of claim 36, further comprising the step of removing bridge molecules not attached to said target diseased before step (e) .
39. A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of:
(a) providing an autologous target diseased cell;
(b) providing a bridge molecule comprising a binding site for a costimulatory molecule on the surface of T cells in said patient mammal;
(c) attaching said bridge molecule to said target diseased cell; (d) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecule attached thereto and administering said collection to said patient mammal; and
(e) administering a pharmaceutically effective amount of one or more cytokines to said patient mammal to increase the levels of one or more primary and costimulatory T-cell activation molecules in said target diseased cell.
40. The method of claim 39, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
41. The method of claim 39, further comprising the step of removing bridge molecules not attached to said target diseased before step (d) .
42. A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of:
(a) providing an autologous target diseased cell; (b) providing a bridge molecule comprising two or more binding sites for two or more different costimulatory molecules on the surface of T cells in said patient mammal;
(c) attaching said bridge molecule to said target diseased cell; and
(d) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecule attached thereto and administering them to said patient mammal .
43. The method of claim 42, wherein said bridge molecule further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and said bridge molecule is attached to said target diseased cell at said antigens.
44. The method of claim 42, further comprising the step of removing bridge molecules not attached to said target diseased before step (d) .
45. A method of curing a patient mammal of diseased cells or reducing growth of diseased cells, comprising the steps of :
(a) providing an autologous target diseased cell; (b) providing two bridge molecules each comprising a binding site for a different costimulatory molecule on the surface of T cells in said patient mammal; (c) attaching said bridge molecules to said target diseased cell; and
(d) thereafter collecting a pharmaceutically effective amount of said target diseased cell with said bridge molecules attached thereto and administering them to said patient mammal .
46. The method of claim 45, wherein each of said bridge molecules further comprises one or more antigen binding sites for one or more antigens on the surface of said target diseased cell and each of said bridge molecules is attached to said target diseased cell at said antigens.
47. The method of claim 45, further comprising the step of removing bridge molecules not attached to said target diseased before step (d) .
48. A bridge molecule for linking a target diseased cell from a patient mammal to an effector cell in said patient mammal, comprising:
(a) a binding site for an antigen on the surface of said target diseased cell; and
(b) two or more binding sites for two or more different costimulatory molecules on the surface of said effector cell .
49. A method of generating cytotoxic leukocytes against diseased cells in a patient mammal, comprising the steps of: (a) providing an immunogenic composition selected from anyone of claims 1-19;
(b) contacting a population of white blood cells with said immunogenic composition for a time period sufficient to react with said immunogenic composition; and
(c) collecting said population of white blood cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1963996P | 1996-06-12 | 1996-06-12 | |
US60/019639 | 1996-06-12 | ||
PCT/US1997/010238 WO1997047271A2 (en) | 1996-06-12 | 1997-06-11 | Cellular vaccines and immunotherapeutics and methods for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4228397A true AU4228397A (en) | 1998-01-07 |
AU727955B2 AU727955B2 (en) | 2001-01-04 |
Family
ID=21794256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU42283/97A Ceased AU727955B2 (en) | 1996-06-12 | 1997-06-11 | Cellular vaccines and immunotherapeutics and methods for their preparation |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0956046A4 (en) |
JP (1) | JP3676380B2 (en) |
CN (1) | CN1221349A (en) |
AU (1) | AU727955B2 (en) |
CA (1) | CA2258082A1 (en) |
WO (1) | WO1997047271A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666609B1 (en) | 1998-12-01 | 2010-02-23 | Shanghai Cp Guojian Pharmaceutical Co. Ltd. | Method and composition for diagnosis of melanocytic lesions |
ES2306670T3 (en) * | 1999-10-22 | 2008-11-16 | Sanofi Pasteur Limited | PROCEDURE FOR INDUCTION AND / OR INTENSIFICATION OF THE IMMUNE RESPONSE TO TUMOR ANTIGENS. |
DE19957470A1 (en) | 1999-11-24 | 2001-06-21 | Actinodrug Pharmaceuticals Gmb | Tetrahydropyrimidine dioxygenase gene and method for enzymatic in vivo and in vitro production of hydroxylated tetrahydropyrimidines |
AUPQ755300A0 (en) * | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
DE10156482A1 (en) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispecific antibody molecule |
CN1659187A (en) * | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | Ferritin fusion proteins for use in vaccines and other applications |
ATE546150T1 (en) * | 2002-06-07 | 2012-03-15 | Zymogenetics Inc | USE OF IL-21 AND MONOCLONAL ANTIBODIES TO TREAT SOLID TUMORS |
CN103736086A (en) * | 2007-02-15 | 2014-04-23 | 曼康公司 | A method for enhancing t cell response |
WO2009143843A1 (en) | 2008-04-17 | 2009-12-03 | Herlev Hospital | Indoleamine 2, 3-dioxygenase based immunotherapy |
CN105925544A (en) * | 2016-06-27 | 2016-09-07 | 武汉思安医疗技术有限公司 | Preparation method and application of 4-1BB-containing lentivirus |
EP3634584A4 (en) * | 2017-06-09 | 2021-04-07 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844893A (en) * | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
-
1997
- 1997-06-11 JP JP50183398A patent/JP3676380B2/en not_active Expired - Fee Related
- 1997-06-11 CA CA002258082A patent/CA2258082A1/en not_active Abandoned
- 1997-06-11 CN CN97195438A patent/CN1221349A/en active Pending
- 1997-06-11 WO PCT/US1997/010238 patent/WO1997047271A2/en not_active Application Discontinuation
- 1997-06-11 EP EP97940524A patent/EP0956046A4/en not_active Withdrawn
- 1997-06-11 AU AU42283/97A patent/AU727955B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0956046A2 (en) | 1999-11-17 |
JPH11514666A (en) | 1999-12-14 |
WO1997047271A3 (en) | 1998-02-12 |
EP0956046A4 (en) | 2004-10-20 |
CA2258082A1 (en) | 1997-12-18 |
WO1997047271A2 (en) | 1997-12-18 |
CN1221349A (en) | 1999-06-30 |
AU727955B2 (en) | 2001-01-04 |
JP3676380B2 (en) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6805869B2 (en) | Cellular vaccines and immunotherapeutics and methods for their preparation | |
JP6630074B2 (en) | Manipulation and delivery of therapeutic compositions of newly isolated cells | |
JP5184732B2 (en) | Compositions and methods of use of monoclonal and polyclonal antibodies specific for T cell subpopulations | |
US7670781B2 (en) | Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal | |
EP3666888A2 (en) | Method for activating t cells for cancer treatment | |
KR20180101540A (en) | Methods and compositions for T cell immunotherapy | |
JP2021509287A (en) | Methods for Transducing Cells with Viral Vectors for Expression of Chimeric Antigen Receptor (CAR) or Transgenic T Cell Receptor (TCR) | |
TW201414837A (en) | Compositions and methods for targeting stromal cells for the treatment of cancer | |
JP2000515364A (en) | Methods of producing labeled activated tumor-specific T cells and their use in tumor therapy | |
TW201934575A (en) | An isolated chimeric antigen receptor and modified T cell contacting same and use thereof | |
AU727955B2 (en) | Cellular vaccines and immunotherapeutics and methods for their preparation | |
US20040247594A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28 | |
US20210292427A1 (en) | Method for treating tumor using immune effector cell | |
WO1997047271A9 (en) | Cellular vaccines and immunotherapeutics and methods for their preparation | |
JP2024086827A (en) | Universal antigen-presenting cells and uses thereof | |
JP2022526856A (en) | Compositions and Methods Containing High Affinity Chimeric Antigen Receptors (CARs) with Cross-Reactivity with Clinically Relevant EGFR Mutant Proteins | |
WO2021148019A1 (en) | Method for transducing cells with viral vector | |
US20050048055A1 (en) | Use of CD40 engagement to alter T cell receptor usage | |
US11701387B2 (en) | Chimeric antigen receptor specific for BDCA2 antigen | |
JP5054875B2 (en) | Cytotoxic T lymphocytes activated by dendritic cell hybrids | |
US20050136066A1 (en) | Cellular vaccines and immunotherapeutics and methods for their preparation | |
US20220160761A1 (en) | Method for t cell activation for cancer treatment | |
Wu et al. | Treatment of hepatocellular carcinoma with the cellular tumor vaccines generated by in vitro modification of tumor cells with non gene transfer approaches | |
KR20220095228A (en) | Methods of Producing Cytotoxic Effector Memory T Cells for the Treatment of T Cells in Cancer | |
AU2001238236B2 (en) | Cytotoxic t lymphocytes activated by dendritic cell hybrids |